Erosive conjunctivitis and punctal stenosis secondary to docetaxel (taxotere).
OBJECTIVE
To report a case of erosive conjunctivitis and punctal stenosis occurring secondarily in a patient who underwent administration of docetaxel.


METHODS
Observational case report: a 58-year-old female with metastatic breast cancer developed erosive conjunctivitis and punctal stenosis after undergoing administration of systemic docetaxel.


RESULTS
Resolution of the erosive conjunctivitis occurred after discontinuation of docetaxel. The punctal stenosis persisted.


CONCLUSIONS
Patients receiving treatment with docetaxel require frequent monitoring to discover potentially irreversible ocular damage.
Skolnick
Craig A
CA
Bascom Palmer Eye Institute, Miami, FL 33418, USA. cskolnick@med.miami.edu
Doughman
Donald J
DJ
D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy; D003231:Conjunctivitis / Q000139:chemically induced*; D000077143:Docetaxel; D005260:Female; D006801:Humans; D007767:Lacrimal Duct Obstruction / Q000139:chemically induced*; D008875:Middle Aged; D017239:Paclitaxel / Q000009:adverse effects* / Q000031:analogs & derivatives*; D043823:Taxoids
D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel